Drug intelligence / Profile preview

VLR6109

Development stage: Preclinical
Lead developer: Velaris Therapeutics
Modality: Antibody-Based Therapeutics

Overview

VLR6109 is an undisclosed preclinical-stage therapeutic candidate being developed for the treatment of pulmonary arterial hypertension (PAH) and other pulmonary or cardiopulmonary diseases. It was originated by Velaris and is being developed following Velaris's acquisition by Alaunos in October 2026. VLR6109 is classified as an undisclosed additional antibody or Fc-conjugate in the company's pipeline, designed with combination use in mind to address the pulmonary treatment paradigm.

Beyond the preview

Go deeper on VLR6109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLR6109.